114 related articles for article (PubMed ID: 12538719)
1. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse.
Katavić V; Lukić IK; Kovacić N; Grcević D; Lorenzo JA; Marusić A
J Immunol; 2003 Feb; 170(3):1540-7. PubMed ID: 12538719
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
3. Retardation in bone resorption after bone marrow ablation in klotho mutant mice.
Yamashita T; Yoshitake H; Tsuji K; Kawaguchi N; Nabeshima Y; Noda M
Endocrinology; 2000 Jan; 141(1):438-45. PubMed ID: 10614667
[TBL] [Abstract][Full Text] [Related]
4. Shared circulation in parabiosis leads to the transfer of bone phenotype from gld to the wild-type mice.
Lukić IK; Kovacić N; Katavić V; Grcević D; Ivcević S; Marusić A
Cell Immunol; 2005 Feb; 233(2):133-9. PubMed ID: 15950207
[TBL] [Abstract][Full Text] [Related]
5. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells.
Fan X; Roy E; Zhu L; Murphy TC; Ackert-Bicknell C; Hart CM; Rosen C; Nanes MS; Rubin J
Endocrinology; 2004 Feb; 145(2):751-9. PubMed ID: 14563699
[TBL] [Abstract][Full Text] [Related]
9. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
[TBL] [Abstract][Full Text] [Related]
10. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
11. Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.
Omokaro SO; Desierto MJ; Eckhaus MA; Ellison FM; Chen J; Young NS
J Immunol; 2009 Mar; 182(6):3414-22. PubMed ID: 19265119
[TBL] [Abstract][Full Text] [Related]
12. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
[TBL] [Abstract][Full Text] [Related]
13. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling.
Mangashetti LS; Khapli SM; Wani MR
J Immunol; 2005 Jul; 175(2):917-25. PubMed ID: 16002690
[TBL] [Abstract][Full Text] [Related]
14. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
15. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
16. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
17. Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells.
Mohamood AS; Trujillo CJ; Zheng D; Jie C; Murillo FM; Schneck JP; Hamad AR
Int Immunol; 2006 Aug; 18(8):1265-77. PubMed ID: 16769751
[TBL] [Abstract][Full Text] [Related]
18. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells.
Chung H; Kang YS; Hwang CS; Moon IK; Yim CH; Choi KH; Han KO; Jang HC; Yoon HK; Han IK
J Korean Med Sci; 2001 Dec; 16(6):769-73. PubMed ID: 11748360
[TBL] [Abstract][Full Text] [Related]
19. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
20. Co-infusion of normal bone marrow partially corrects the gld T-cell defect. Evidence for an intrinsic and extrinsic role for Fas ligand.
Sobel ES; Kakkanaiah VN; Kakkanaiah M; Cohen PL; Eisenberg RA
J Immunol; 1995 Jan; 154(1):459-64. PubMed ID: 7527822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
